Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × Glutamine × Clear all

NCT01607879 2023-09-22

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Phase 2 Completed

48 enrolled 15 charts

EndocrineGenitourinary

Prostatic Neoplasms, Multiple Endocrine Neoplasia Type 1